Clinical trial

AZD2171 and Pemetrexed Disodium in Treating Patients With Relapsed Non-Small Cell Lung Cancer

NCT00410904

Drugs and interventions used in this trial

2 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

DRUG · Unmapped registry intervention cediranib maleate Find medicine records · Find other trials using this name

DRUG · Mapped RxNorm record pemetrexed disodium Normalized identity: pemetrexed disodiumView linked drug · Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

AZD2171 and Pemetrexed Disodium in Treating Patients With Relapsed Non-Small Cell Lung Cancer

Design: INTERVENTIONAL · Status: COMPLETED · Phase: PHASE2

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2006-10-01

PhasePHASE2

Conditions

Recurrent Non-small Cell Lung Cancerunresolved

Interventions

cediranib maleateDRUG

pemetrexed disodiumDRUG · verified · RxNorm: pemetrexed disodium

Sponsors & collaborators

National Cancer Institute (NCI)lead sponsor

Mapped research locations

BaltimoreMaryland, United States1 DetroitMichigan, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT00410904 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.